StockData
Cellectar Biosciences, Inc. logo

Cellectar Biosciences, Inc. (CLRB) stock

CLRBNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 6/30
$1.01−0.13 (-11.40%)

Close on Nov 16, 2026Market cap $9.55MP/E –Yield –

Cellectar Biosciences ebitda

EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.

Cellectar Biosciences's ebitda for the twelve months ending Dec 31, 2025 was -$22.77M. For fiscal 2025 it was -$22.77M. The highest annual figure on record is -$3.61M in fiscal 2010.

Annual ebitda

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$22.77M–
FY2024Dec 31, 2024-$51.49M–
FY2023Dec 31, 2023-$38.77M–
FY2022Dec 31, 2022-$28.67M–
FY2021Dec 31, 2021-$23.98M–
FY2020Dec 31, 2020-$15.15M–
FY2019Dec 31, 2019-$14.05M–
FY2018Dec 31, 2018-$13.25M–
FY2017Dec 31, 2017-$12.05M–
FY2016Dec 31, 2016-$9.09M–
FY2015Dec 31, 2015-$8.40M–
FY2014Dec 31, 2014-$9.52M–
FY2013Dec 31, 2013-$11.98M–
FY2012Dec 31, 2012-$8.26M–
FY2011Dec 31, 2011-$6.45M–
FY2010Dec 31, 2010-$3.61M–

Quarterly ebitda

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q4 FY2025Dec 31, 2025-$5.64M–
Q3 FY2025Sep 30, 2025-$4.80M–
Q2 FY2025Jun 30, 2025-$5.98M–
Q1 FY2025Mar 31, 2025-$6.34M–
Q4 FY2024Dec 31, 2024-$12.68M–
Q3 FY2024Sep 30, 2024-$13.26M–
Q2 FY2024Jun 30, 2024-$13.64M–
Q1 FY2024Mar 31, 2024-$11.91M–
Q4 FY2023Dec 31, 2023-$12.48M–
Q3 FY2023Sep 30, 2023-$9.37M–
Q2 FY2023Jun 30, 2023-$8.26M–
Q1 FY2023Mar 31, 2023-$8.66M–
Q4 FY2022Dec 31, 2022-$7.38M–
Q3 FY2022Sep 30, 2022-$7.78M–
Q2 FY2022Jun 30, 2022-$7.40M–
Q1 FY2022Mar 31, 2022-$6.10M–
Q4 FY2021Dec 31, 2021-$5.88M–
Q3 FY2021Sep 30, 2021-$5.78M–
Q2 FY2021Jun 30, 2021-$5.99M–
Q1 FY2021Mar 31, 2021-$6.32M–
Q4 FY2020Dec 31, 2020-$3.76M–
Q3 FY2020Sep 30, 2020-$3.87M–
Q2 FY2020Jun 30, 2020-$3.59M–
Q1 FY2020Mar 31, 2020-$3.92M–
Q4 FY2019Dec 31, 2019-$3.35M–
Q3 FY2019Sep 30, 2019-$3.93M–
Q2 FY2019Jun 30, 2019-$3.17M–
Q1 FY2019Mar 31, 2019-$3.60M–
Q4 FY2018Dec 31, 2018-$3.85M–
Q3 FY2018Sep 30, 2018-$3.07M–
Q2 FY2018Jun 30, 2018-$2.89M–
Q1 FY2018Mar 31, 2018-$3.44M–
Q4 FY2017Dec 31, 2017-$2.84M–
Q3 FY2017Sep 30, 2017-$3.38M–
Q2 FY2017Jun 30, 2017-$3.12M–
Q1 FY2017Mar 31, 2017-$2.73M–
Q4 FY2016Dec 31, 2016-$2.56M–
Q3 FY2016Sep 30, 2016-$2.38M–

More Cellectar Biosciences figures

See a number that looks wrong?